CKAP2 and bone metastasis: The LUAD bone metastasis patients were accompanied by decreased levels of CKAP2 autoantibody, however, the bioinformatic analysis revealed that CKAP2 was correlated with poorer clinical outcomes in NSCLC, indicating that CKAP2 autoantibody may have positive functions in confronting tumors.